GDF-15治疗对肝癌化疗敏感性影响的分析

Analysis of GDF-15 treatment for the sensitivity of liver cancer chemotherapy

目的探讨生长分化因子-15（GDF～15）治疗对于肝癌化疗敏感性的影响。方法通过采用免疫组织化学方法SP分别检测行GDF-15治疗与未行GDF-15治疗的肝癌组织中丝氨酸，苏氨酸蛋白激酶受体（RSK）及多药耐药相关蛋白（NRPI）的表达情况，从而探讨GDF-15对于肝癌化疗敏感性的影响。结果在20例行GDF-15治疗组，其丝氨酸，苏氨酸蛋白激酶受体（RSK）表达强度为：0．4358±0．01246，15例未行GDF-15治疗组，其丝氨酸／苏氨酸蛋白激酶受体（RSK）表达强度为：0．3012±0．01278，前者表达强度明显高于后者（P〈0．05），因此GDF-15治疗组，其疗效好于非GDF-15治疗组；在20例行GDF-15治疗组，其多药耐药相关蛋白（MRPI）表达强度为：0．3574±0．02159，15例未行GDF-15治疗组，其多药耐药相关蛋白（MRPI）表达强度为：0．3101±0．01108，前者表达强度明显高于后者（P〈0．05），因此GDF-15治疗组，其可增加肝癌对药物的耐药性。结论在行肝癌化疗时，加用GDF-15的治疗可增强机体抗肿瘤免疫，但是另一方面可以增加肝癌对化疗药物的耐药性，减低其敏感性，因此，对于肝癌的化疗，加用CDF-15的治疗可降低其效果。

Objective To investigate the effecacy of GDF-15 treatment for liver cancer chemosensitivity. Methods Immuno- histochemical SP was used to detect expressions of Serine/threonine protein kinase receptor （RSK） and multi-resistant protein （MRPI） in liver cancer of two groups, one was using GDF-15 treatment and the other was not, explored the effect of GDF 15-for chemosensitivity of liver cancer. Results in 20 cases with GDF-15 treatment, its serine/threonine protein kinase receptor （RSK） expression intensity was 0.4358 ± 0.01246, while in 15 cases without GDF-15, the serine/threonine protein kinase receptor （RSK） expression intensity was 0.3012 ± 0.01278. The former expression intensity was significantly higher than the other（P〈0.05）, and therefore the efficacy of group with GDF-15 was better than the group without GDF-15.In 20 cases with GDF-15, the multidrug resistance-associated protein （MRPI） expression intensity was 0.3574 ± 0.02159, while in 15 cases without GDF-15, the multidrug resistance-associated protein （MRPI） expression intensity was 0.3101 ± 0.01108. The former expression level was significantly higher than the other （P 〈0.05）. Therefore the treatment group GDF-15 had higher liver cancer drug resistance. Conclusion HCC line chemotherapy, home GDF-15 treatment can enhance the body＇s anti-tumor immunity, but on the other side it can increase liver resistance to chemotherapeutic drugs, and reduce their sensitivity. Therefore, for liver cancer chemotherapy, using GDF -15 treatment can reduce its effectiveness.